GoAI
Get started
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIV

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$36.3371

+$0.025 · +0.07%

Aug 24, 11:18 AM ET

ROIV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

4

Overpriced

Momentum

71

Gaining

Sentiment

59

Mixed

Risk resilience

73

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Industry
Biotechnology
Sector
Healthcare
Headquarters
GB
CEO
Matthew Gline
Listed since
Dec 8, 2020
Employees
721

Market position

Volume
1.36M
0.24× average
Average volume
5.8M
Average daily volume
Market cap
26.24B USD
Beta
1.13
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
17.9B USD
EV / EBITDA
-68.54×
Earnings yield
-1.56%
Free cash flow yield
-3.95%

Profitability & efficiency

Return on equity
-6.62%
Return on assets
-5.23%
Return on invested capital
-23.55%

Financial health

Current ratio
18.37×
Altman Z-score
41.5
Piotroski F-score
0 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends16180%4638%-6904%-18446%Gross margin, FY2021: 83.78%Gross margin, FY2022: 90.38%Gross margin, FY2023: 95.11%Gross margin, FY2024: 96.86%Gross margin, FY2025: 84.44%Operating margin, FY2021: -2191.78%Operating margin, FY2022: -2565.85%Operating margin, FY2023: -2521.71%Operating margin, FY2024: -3833.27%Operating margin, FY2025: -15560.57%Net margin, FY2021: -1528.89%Net margin, FY2022: -3200.22%Net margin, FY2023: 13294.18%Net margin, FY2024: -591.96%Net margin, FY2025: -3629.19%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 83.78%. Gross margin FY2022 90.38%. Gross margin FY2023 95.11%. Gross margin FY2024 96.86%. Gross margin FY2025 84.44%. Operating margin FY2021 -2191.78%. Operating margin FY2022 -2565.85%. Operating margin FY2023 -2521.71%. Operating margin FY2024 -3833.27%. Operating margin FY2025 -15560.57%. Net margin FY2021 -1528.89%. Net margin FY2022 -3200.22%. Net margin FY2023 13294.18%. Net margin FY2024 -591.96%. Net margin FY2025 -3629.19%.

Income trends

Revenue

8.26M USD-71.57%

Operating income

−1.29B USD-15.41%

Net income

−299.77M USD-74.30%
Income trends across reported periods4.91B USD2.66B USD404.97M USD−1.85B USDRevenue, FY2021: 55.29M USDRevenue, FY2022: 31.53M USDRevenue, FY2023: 32.71M USDRevenue, FY2024: 29.05M USDRevenue, FY2025: 8.26M USDOperating income, FY2021: −1.21B USDOperating income, FY2022: −809.01M USDOperating income, FY2023: −824.93M USDOperating income, FY2024: −1.11B USDOperating income, FY2025: −1.29B USDNet income, FY2021: −845.26M USDNet income, FY2022: −1.01B USDNet income, FY2023: 4.35B USDNet income, FY2024: −171.98M USDNet income, FY2025: −299.77M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 55.29M USD. Revenue FY2022 31.53M USD. Revenue FY2023 32.71M USD. Revenue FY2024 29.05M USD. Revenue FY2025 8.26M USD. Operating income FY2021 −1.21B USD. Operating income FY2022 −809.01M USD. Operating income FY2023 −824.93M USD. Operating income FY2024 −1.11B USD. Operating income FY2025 −1.29B USD. Net income FY2021 −845.26M USD. Net income FY2022 −1.01B USD. Net income FY2023 4.35B USD. Net income FY2024 −171.98M USD. Net income FY2025 −299.77M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue8.26M USD29.05M USD32.71M USD31.53M USD55.29M USD
Cost of goods sold1.29M USD911K USD1.6M USD3.03M USD8.97M USD
Gross profit6.98M USD28.14M USD31.11M USD28.5M USD46.32M USD
Research and development681.81M USD550.41M USD439.91M USD454.06M USD483.04M USD
Selling, general, and administrative610.47M USD591.41M USD416.13M USD383.45M USD775.03M USD
Operating expenses1.29B USD1.14B USD856.04M USD837.51M USD1.26B USD
Interest income178.11M USD258.38M USD146.43M USD32.18M USD369K USD
Interest expense——34.78M USD27.97M USD7.04M USD
Depreciation and amortization3.35M USD14.07M USD22.04M USD18.86M USD5.93M USD
Operating income−1.29B USD−1.11B USD−824.93M USD−809.01M USD−1.21B USD
Net income−299.77M USD−171.98M USD4.35B USD−1.01B USD−845.26M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+20.47%
11 comparable reports
Latest EPS result
-0.33
Estimate -0.3 · Miss by 10.14%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.17-0.26-0.36-0.45Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual -0.23, estimate -0.253, surprise +9.04%, Beat. Q2 2025, reported May 29, 2025: actual -0.29, estimate -0.264, surprise -10.05%, Miss. Q3 2025, reported Aug 11, 2025: actual -0.252, estimate -0.25, surprise -0.82%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.202, estimate -0.32, surprise +36.86%, Beat. Q1 2026, reported Feb 6, 2026: actual -0.24, estimate -0.3, surprise +19.88%, Beat. Q2 2026, reported May 20, 2026: actual -0.279, estimate -0.289, surprise +3.49%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.33, estimate -0.3, surprise -10.14%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.41, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates58.28M39.27M20.25M1.23MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 10, 2025: actual 9.02M USD, estimate 5M USD, surprise +80.36%, Beat. Q2 2025, reported May 29, 2025: actual 7.57M USD, estimate 54.07M USD, surprise -86.00%, Miss. Q3 2025, reported Aug 11, 2025: actual 2.17M USD, estimate 7.3M USD, surprise -70.28%, Miss. Q4 2025, reported Nov 10, 2025: actual 1.57M USD, estimate 5.62M USD, surprise -72.04%, Miss. Q1 2026, reported Feb 6, 2026: actual 2M USD, estimate 5.08M USD, surprise -60.65%, Miss. Q2 2026, reported May 20, 2026: actual 2.52M USD, estimate 3.41M USD, surprise -26.20%, Miss. Q3 2026, reported Aug 6, 2026: actual 1.44M USD, estimate 2.06M USD, surprise -29.89%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 3.3M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$40.00

10.12% upside
Past 12 months12-month forecastHigh $42.00Average $40.00Low $36.00

Rating distribution

15 ratings
Strong buy00%
Buy1493%
Hold17%
Sell00%
Strong sell00%

ROIV peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding ROIV

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
565.21M
Weight
0.44%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.095-0.88%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
543.88M
Weight
0.02%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.77-0.39%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
392.44M
Weight
0.21%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$302.82-0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
226.94M
Weight
0.51%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$354.33-1.20%
Invesco S&P MidCap Momentum ETF logoInvesco S&P MidCap Momentum ETFXMMO
Market value
193.08M
Weight
2.59%
AUM
7.45B USD
Expense ratio
0.35%
Price / 1D
$154.23-1.82%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
176.08M
Weight
0.18%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.63-0.77%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
139.3M
Weight
1.30%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$211.55-0.94%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
135.29M
Weight
1.19%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$163.9-1.10%

Continue in GoAI

Research ROIV

research.disclaimer